Altamira Therapeutics (CYTO) Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal Spray Jun 8, 2022 08:49AM
Altamira Therapeutics (CYTO) Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Omicron Variant Mar 11, 2022 09:01AM
Altamira Therapeutics (CYTO) Announces Positive In vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Delta Variant Nov 12, 2021 09:01AM
Altamira Therapeutics (CYTO) Reports Protective Effects of Bentrio Nasal Spray Against Influenza A Virus (H1N1) Aug 6, 2021 09:08AM